Related Experiment Video
Updated: Aug 3, 2025
07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
8.3K
Drugs in Development for Chronic Spontaneous Urticaria
Journal of Drugs in Dermatology : JDD
|April 7, 2023
Summary
New therapies are emerging for chronic spontaneous urticaria (CSU), a difficult-to-treat condition. Future treatments may involve personalized medicine based on a patient's specific autoimmune profile.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Chronic spontaneous urticaria (CSU) is a significant unmet medical need, with many patients experiencing inadequate symptom control.
- Recent breakthroughs in understanding CSU pathophysiology pave the way for more effective therapeutic strategies.
- Personalized treatment selection based on autoimmune endotypes may become a future standard of care.
Approach:
- This review synthesizes current knowledge on the pathogenesis of chronic spontaneous urticaria.
- It examines existing and emerging treatment options for CSU.
- Data on investigational drugs for CSU, sourced from ClinicalTrials.gov, are analyzed.
Key Points:
- CSU pathogenesis is complex, involving multiple immune pathways.
- Current treatments for CSU offer variable efficacy.
- Numerous novel therapeutic agents targeting different mechanisms are under development for CSU.
Conclusions:
- Advances in understanding CSU are driving the development of targeted therapies.
- The pipeline of drugs in development offers hope for improved patient outcomes.
- Personalized medicine approaches hold promise for optimizing CSU treatment.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
379
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
379
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
367
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
367
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
323
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
323
01:27Allergic Drug Reactions
905
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
905
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
358
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
358
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
327
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
327